Fortress Biotech, Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off
Fortress Biotech, Inc. (FBIO) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $0 for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2026-03-31
- Fortress Biotech, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2025-03-31 was $0.00.
- Fortress Biotech, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Fortress Biotech, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2023-12-31 was $31.00K, a 95.07% decline year-over-year.
- Fortress Biotech, Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2023-09-30 was $60.00K, a 27.66% increase year-over-year.
- Fortress Biotech, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2024 was $252.00K, a 94.17% decline from fiscal 2023.
- Fortress Biotech, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2023 was $4.32M, a 538.70% increase from fiscal 2022.
- Fortress Biotech, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2022 was $677.00K, a 95.67% decline from fiscal 2021.
- Fortress Biotech, Inc. research and development asset acquired other than through business combination, written-off for fiscal 2021 was $15.63M, a 451.34% increase from fiscal 2020.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month as first filed | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-05-15 | |||||||
| 2024-12-31 | $252.00K 10-K · filed 2026-03-31 | |||||||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-15 | $31.00K derived: sum of 2 quarters · filed 2025-05-15 | $91.00K derived: sum of 3 quarters · filed 2025-05-15 | $94.00K derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | $31.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $91.00K derived: sum of 2 quarters · filed 2025-03-31 | $94.00K derived: sum of 3 quarters · filed 2025-03-31 | $4.32M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $60.00K 10-Q · filed 2024-11-14 | $63.00K derived: sum of 2 quarters · filed 2024-11-14 | $4.29M 10-Q · filed 2024-11-14 | $4.92M derived: sum of 4 quarters · filed 2024-11-14 | ||||
| 2023-06-30 | $3.00K 10-Q · filed 2024-08-13 | $4.23M 10-Q · filed 2024-08-13 | $4.86M derived: sum of 3 quarters · filed 2024-08-13 | $4.91M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $4.23M 10-Q · filed 2024-05-15 | $4.86M derived: sum of 2 quarters · filed 2024-05-15 | $4.91M derived: sum of 3 quarters · filed 2024-05-15 | $4.91M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $629.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $676.00K derived: sum of 2 quarters · filed 2024-03-28 | $677.00K derived: sum of 3 quarters · filed 2024-03-28 | $677.00K 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $47.00K 10-Q · filed 2023-11-14 | $48.00K derived: sum of 2 quarters · filed 2023-11-14 | $48.00K 10-Q · filed 2023-11-14 | |||||
| 2022-06-30 | $1.00K 10-Q · filed 2023-08-14 | $1.00K 10-Q · filed 2023-08-14 | ||||||
| 2021-12-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $753.00K derived: sum of 2 quarters · filed 2023-03-31 | $11.76M derived: sum of 3 quarters · filed 2023-03-31 | $15.63M 10-K · filed 2023-03-31 | ||||
| 2021-09-30 | $713.00K 10-Q · filed 2022-11-14 | $11.72M derived: sum of 2 quarters · filed 2022-11-14 | $15.59M 10-Q · filed 2022-11-14 | $12.40M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | $11.00M 10-Q · filed 2022-08-11 | $11.13M 10-Q · filed 2022-08-11 | $11.69M derived: sum of 3 quarters · filed 2022-08-11 | $12.14M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $126.00K 10-Q · filed 2022-05-12 | $20.03M 10-Q · filed 2021-05-17 | $682.00K derived: sum of 2 quarters · filed 2022-05-12 | $1.14M derived: sum of 3 quarters · filed 2022-05-12 | $2.71M derived: sum of 4 quarters · filed 2022-05-12 | |||
| 2020-12-31 | $556.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $1.01M derived: sum of 2 quarters · filed 2022-03-28 | $2.58M derived: sum of 3 quarters · filed 2022-03-28 | $2.83M 10-K · filed 2022-03-28 | $61.27M 10-K · filed 2021-03-31 | |||
| 2020-09-30 | $458.00K 10-Q · filed 2021-11-15 | $2.03M derived: sum of 2 quarters · filed 2021-11-15 | $2.28M 10-Q · filed 2021-11-15 | $2.24M 10-Q · filed 2020-11-09 | $90.78M derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | $1.57M 10-Q · filed 2021-08-16 | $1.82M 10-Q · filed 2021-08-16 | $1.80M 10-Q · filed 2020-08-10 | $90.32M derived: sum of 3 quarters · filed 2021-08-16 | $91.02M derived: sum of 4 quarters · filed 2021-08-16 | |||
| 2020-03-31 | $14.87M 10-Q · filed 2021-05-17 | $250.00K 10-Q · filed 2020-05-11 | $88.75M derived: sum of 2 quarters · filed 2021-05-17 | $89.45M derived: sum of 3 quarters · filed 2021-05-17 | $89.65M derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2019-12-31 | $73.89M derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-04-09 | $74.59M derived: sum of 2 quarters · filed 2021-04-09 | $74.79M derived: sum of 3 quarters · filed 2021-04-09 | $75.24M 10-K/A · filed 2021-04-09 | $6.00M 10-K · filed 2020-03-16 | |||
| 2019-09-30 | $700.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $900.00K derived: sum of 2 quarters · filed 2020-11-09 | $1.35M 10-Q · filed 2020-11-09 | $1.32M derived: sum of 4 quarters · filed 2020-11-09 | ||||
| 2019-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $650.00K 10-Q · filed 2020-08-10 | $620.00K derived: sum of 3 quarters · filed 2020-08-10 | $4.33M derived: sum of 4 quarters · filed 2020-08-10 | ||||
| 2019-03-31 | $450.00K 10-Q · filed 2020-05-11 | $420.00K derived: sum of 2 quarters · filed 2020-05-11 | $4.13M derived: sum of 3 quarters · filed 2020-05-11 | $4.13M derived: sum of 4 quarters · filed 2020-05-11 | ||||
| 2018-12-31 | -$30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $3.68M derived: sum of 2 quarters · filed 2020-03-16 | $3.68M derived: sum of 3 quarters · filed 2020-03-16 | $3.77M 10-K · filed 2020-03-16 | ||||
| 2018-09-30 | $3.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $3.71M derived: sum of 2 quarters · filed 2019-11-12 | $3.80M 10-Q · filed 2019-11-12 | $4.57M derived: sum of 4 quarters · filed 2019-11-12 | ||||
| 2018-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $98.00K 10-Q · filed 2019-08-09 | $868.00K derived: sum of 3 quarters · filed 2019-08-09 | $1.17M derived: sum of 4 quarters · filed 2019-08-09 | ||||
| 2018-03-31 | $97.00K 10-Q · filed 2019-05-10 | $867.00K derived: sum of 2 quarters · filed 2019-05-10 | $1.17M derived: sum of 3 quarters · filed 2019-05-10 | $3.00M derived: sum of 4 quarters · filed 2019-05-10 | ||||
| 2017-12-31 | $770.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-18 | $1.07M derived: sum of 2 quarters · filed 2019-03-18 | $2.90M derived: sum of 3 quarters · filed 2019-03-18 | $4.16M 10-K · filed 2019-03-18 | ||||
| 2017-09-30 | $299.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $2.13M derived: sum of 2 quarters · filed 2018-11-09 | $3.39M 10-Q · filed 2018-11-09 | $4.09M derived: sum of 4 quarters · filed 2018-11-09 | ||||
| 2017-06-30 | $1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $3.10M 10-Q · filed 2018-08-09 | $3.79M derived: sum of 3 quarters · filed 2018-08-09 | $4.79M derived: sum of 4 quarters · filed 2018-08-09 | ||||
| 2017-03-31 | $1.26M 10-Q · filed 2018-05-10 | $1.96M derived: sum of 2 quarters · filed 2018-05-10 | $2.96M derived: sum of 3 quarters · filed 2018-05-10 | $5.07M derived: sum of 4 quarters · filed 2018-05-10 | ||||
| 2016-12-31 | $695.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $1.70M derived: sum of 2 quarters · filed 2018-03-16 | $3.80M derived: sum of 3 quarters · filed 2018-03-16 | $3.84M 10-K · filed 2018-03-16 | $3.79M 10-K · filed 2017-03-16 | |||
| 2016-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $3.11M derived: sum of 2 quarters · filed 2017-11-09 | $3.14M 10-Q · filed 2017-11-09 | $3.10M 10-Q · filed 2016-11-09 | $4.63M derived: sum of 4 quarters · filed 2018-03-16 | |||
| 2016-06-30 | $2.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $2.14M 10-Q · filed 2017-08-09 | $2.10M 10-Q · filed 2016-08-09 | $3.63M derived: sum of 3 quarters · filed 2018-03-16 | $4.92M derived: sum of 4 quarters · filed 2018-03-16 | |||
| 2016-03-31 | $35.00K 10-Q · filed 2017-05-10 | $1.52M derived: sum of 2 quarters · filed 2018-03-16 | $2.81M derived: sum of 3 quarters · filed 2018-03-16 | $4.51M derived: sum of 4 quarters · filed 2018-03-16 | ||||
| 2015-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $2.78M derived: sum of 2 quarters · filed 2018-03-16 | $4.48M derived: sum of 3 quarters · filed 2018-03-16 | $11.41M 10-K · filed 2018-03-16 | $10.45M 10-K · filed 2016-03-15 | |||
| 2015-09-30 | $1.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $2.99M derived: sum of 2 quarters · filed 2016-11-09 | $9.92M 10-Q · filed 2016-11-09 | |||||
| 2015-06-30 | $1.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $8.63M 10-Q · filed 2016-08-09 | ||||||
| 2015-03-31 | $6.93M 10-Q · filed 2016-05-10 | |||||||
| 2014-12-31 | $0.00 10-K · filed 2017-03-16 | |||||||
| 2013-12-31 | $0.00 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |